

individual sequences are normally deemed to constitute independent and distinct inventions, "in most cases, up to 10 independent and distinct nucleotide sequences will be examined in a single application without restriction." Here the Examiner has required restriction between five sequences, half the number Patent Office policy indicates are normally examined without a requirement for restriction.

Under Patent Office policy, the restriction requirement to one sequence appears to be improper. Claims 7-18 should not be subject to restriction and all claims 7-18 should be examined.

Please charge any additional fees due, or deposit any overpayments, to Deposit Account No. 13-1175 of the undersigned.

Respectfully,

MALLINCKRODT & MALLINCKRODT



Robert R. Mallinckrodt
Attorney for Applicant
Registration No. 26,565
Customer No. 27469

December 23, 2002
Salt Lake City, UT

gen:p\146 Impact Di\002-tr response.wpd